B eta thalassemia major (BTm) is an autosomal recessive disorder caused by a severely decreased synthesis of normal beta globin chains. The widely used therapy for this disorder is regular red blood cell transfusion, which alleviates anemia and suppresses ineffective erythropoiesis. 1 However, lifetime transfusion therapy causes iron overload and hemosiderosis in different organs (i.e., heart, liver, kidneys) so that cardiac hemosiderosis is the most common cause of death in these patients. 2 The mortality rate may be related to the side effect of iron chelation therapy used for treatment of organ-specific hemosiderosis. 3 despite receiving regular and intense iron chelation therapy, the iron overloading complications in some patients with BTm is more serious and more frequent than in others. We hypothesized that the coexistence of some genetic variations modifying iron metabolism in patients with BTm may contribute to the variability of phenotypic expression of iron overloading complications in these patients. 4 Genetic variations in the genes responsible for iron homeostasis can aggravate the complications of iron overload and accelerate the development of organspecific hemosiderosis in patients with BTm. 4 HFe C282y and H63d mutations are the common causes Objectives: Organ-specific hemosiderosis and iron overload complications are more serious and more frequent in some patients with beta thalassemia major (BTm) compared with others. We investigated whether coinheritance of HFe H63d or C282y gene mutations in patients with BTm contributes to the phenotypic variation of iron overload complications and assessed the correlation of cardiac and hepatic hemosiderosis with plasma ferritin levels. Methods: We studied 60 patients with BTm with a mean age of 17.5±9.1 years from the northwest of Iran. HFe gene mutations were analyzed using the polymerase chain reaction-restriction fragment length polymorphism method. Cardiac and hepatic hemosiderosis was assessed using T2*magnetic resonance imaging (mrI). Ferritin levels were measured using the enzyme immunoassay method. Results: Ferritin levels showed a strong inverse correlation with hepatic T2*mrI values (r = -0.631, p = 0.001) but a poor correlation with cardiac T2*mrI values (r = -0.297, p = 0.044). The correlation between cardiac T2*mrI values and hepatic T2*mrI values was poor and insignificant (r = 0.287, p = 0.058). Genotype and allele distribution of HFe H63d and C282y mutation did not differ significantly between patients with and without hepatic or cardiac hemosiderosis (p > 0.050). However, carriers of HFe 63d allele had significantly higher ferritin levels compared with non-carriers (1 903±993 vs. 992±683, p < 0.001). Conclusions: Cardiac T2*mrI values showed a poor correlation with hepatic T2*mrI values and ferritin levels. accurate assessment of cardiac iron overload in patients with BTm can only be done using the T2*mrI technique. additionally, HFe H63d is a significant determinant factor for elevated ferritin levels in BTm patients. of iron overload in different populations. 5 The HFe C282y mutation reduces the cell surface expression of protein thereby preventing the HFe molecule from interacting with β2-microglobulin. 6 The HFe H63d mutation is due to a C-to-G change at nucleotide 187 converts histidine (H) at position 63 to aspartic acid (d) in the HFe protein. The mutant d allele causes a defective interaction between HFe molecule, β2-microglobulin and transferrin receptor on the cell surface, which can lead to increased iron absorption and hemosiderosis. [6] [7] [8] [9] The frequency of two HFe gene mutations (C282y and H63d) was reported to be high in Caucasian and Indian population. 9 no comprehensive study exists looking at the prevalence of these two HFe gene mutations in the Iranian population. However, one study of Iranian patients found that the HFe C282y gene mutation was not present in any of 50 normal control subjects whereas the HFe H63d gene mutation was detected in 26% of control subjects. 10 The HFe H63d and C282y mutations were found to be associated with elevated serum iron and ferritin levels in patients with BTm. This may confer increased susceptibility to the development of organ-specific hemosiderosis in these patients. 4, 6, 7 However, studies investigating the role of HFe C282y and H63d gene mutations in the development of cardiac and hepatic hemosiderosis in patients with BTm are limited, especially in the Iranian population. [11] [12] [13] [14] moreover, accurate assessment of iron overload and organ-specific hemosiderosis in patients with BTm may play important roles in managing these patients better. The principal method to assess iron loading includes measurement of ferritin levels and the liver iron concentration (lIC) assay. 15, 16 moreover, T2* magnetic resonance imaging (mrI) as a non-invasive method is currently the gold standard approach for evaluating organ-specific hemosiderosis. 16, 17 However, T2*mrI is expensive, not widely available, and its interpretation needs an expert radiologist. also, mrI scan is not an easy procedure in children. many studies have investigated the correlation between plasma ferritin levels and T2*mrI values of heart and liver to determine whether ferritin levels could be used as a suitable index to assess iron overload status in such patients. However, conflicting results have been reported. [18] [19] [20] [21] [22] Our study aimed to investigate whether the HFe H63d and C282y gene mutations could contribute to the development of cardiac and hepatic hemosiderosis in patients with BTm. We also investigated the association of these mutations with some biochemical iron markers and the correlation of hepatic and cardiac T2* mrI values and lIC with each other and plasma ferritin levels.
M ET H O D S
Between February and September 2016, we conducted a cross-sectional study of 60 patients with BTm who were admitted to the mousavi Hospital of the Zanjan province, Iran. Twenty-eight women and 32 men with a mean age of 17.5±9.1 years were enrolled. Patients with BTm (diagnosed by molecular methods) who were on regular red blood cell transfusion (at least two per month) and received chelation therapy were included in the study. Patients suffering from hepatitis B or hepatitis C infection or any other disease such as malignancy, renal disease, inflammation, and autoimmune disorders were excluded. Patients with thalassemia minor and intermedia or patients who refused to be part of the study were excluded. Written informed consent was obtained from all participants, and the study was approved by the ethical committee of Zanjan university of medical Science (ethical committee code: ZumS.reC.1393.166).
Fasting blood samples were collected from all patients in ethylenediaminetetraacetic acid (edTa) containing tubes. Plasma iron and transferrin levels were measured by routine colorimetric methods using commercially available kits (Pars. azmoon ltd., Tehran, Iran). Transferrin saturation index was calculated by the ratio of plasma iron and transferrin levels multiplied by 100. Ferritin levels were determined by the enzyme immune assay (elISa kit, Pishtaz Teb ltd, Tehran, Iran) according to the manufacturer's protocol. For genotyping of HFe H63d and C282y mutations, dna was extracted from blood leukocytes using a commercially available kit (Geno Plus Genomic dna mini, viogene, Poland) according to the manufacturer's instructions. detection of HFe H63d and C282y mutations was conducted using the polymerase chain reaction-restriction fragment length polymorphism (PCr-rFlP) method using BclI and rsaI restriction enzymes as described previously. 23 The amplicon size of HFe H63d mutation was 207 bp, and its digestion with BclI enzyme results in 138 bp and 69 bp fragments in the presence of H allele and an undigested 207 bp fragment in the presence of d allele. The amplicon size of HFe C282y mutation was 390 bp, and its digestion with rsaI enzyme results in 250 bp and 140 bp fragments in the presence of 282C allele and 250 bp, 111 bp and 29 bp in the presence of 282y allele. all patients underwent mrI using a 1.5 Tesla scanner (achieva 1.5T a-series, Philips medical Systems) at Pardis noor Clinic, Tehran, Iran. The protocol used for T2*mrI measurements in all patients was based on the royal Brompton procedures utilizing a single breath, multi-echo, fast gradient-echo sequence. all patients were categorized into four groups based on their T2*mrI milliseconds (ms) results according to following cutoff points; cardiac hemosiderosis: normal > 20 ms, mild: 14-20 ms, moderate: 10-14 ms, severe < 10 ms; hepatic hemosiderosis: normal > 6. 3 
R E SU LTS
The investigated population was 60 BTm patients including 28 female and 32 men who were on regular red blood cell transfusion at intervals of 2-4 weeks. The mean ages of the BTm patients were 17.5±9.1 years. The rate of splenectomy in the study population was 25.0% (15 out of 60 BTm patients). Of the 60 patients, 10 (16.6%) had developed alloantibody with anti-K the most common. all patients were transfused with leukoreduced packed red blood cells. all patients received regular iron chelation therapy from early childhood. Thirty-five patients were under regular iron chelation therapy with desferrioxamine (30-50 mg/kg/day), which was administered subcutaneously. The 25 patients that had an intolerance to desferrioxamine were chelated with oral iron chelator deferasirox (30-40 mg/kg/day). abnormal hepatic iron load (T2*mrI < 6.3 ms) and abnormal cardiac iron load (T2*mrI < 20 ms) was detected in 25 (41.6%) and 23 (38.3%) patients with BTm, respectively. detailed information regarding the cardiac and hepatic T2*mrI values in the BTm patients are presented in Table 1 . The comparison of BTm patients with and without hemosiderosis revealed that plasma ferritin levels, iron levels, and transferrin saturation index were significantly higher in BTm patients with hepatic hemosiderosis than those without hepatic hemosiderosis (p = 0.021; p = 0.001; p = 0.010, respectively). Similarly, these values were significantly higher in BTm patients with cardiac hemosiderosis than those without cardiac hemosiderosis (p = 0.008; p = 0.001; p = 0.012, respectively) [ Table 2 ]. The correlation between plasma ferritin levels and hepatic T2*mrI values indicated a statistically significant inverse correlation (r = -0.631, p = 0.001) [ Figure 1a ]. Plasma ferritin levels showed a strong direct correlation with lIC (r = 0.701, p = 0.007). a strong inverse correlation was seen between the hepatic T2*mrI values and lIC (r = -0.812, p < 0.001) [ Table 3 ]. However, the inverse correlation between plasma ferritin levels and cardiac T2*mrI values was poor (r = -0.297, p = 0.044) [ Figure 1b ]. also, the inverse correlation between cardiac T2*mrI values and lIC was poor and insignificant (r = -0.285, p = 0.270). moreover, the correlation between cardiac T2*mrI and hepatic T2*mrI values was also weak and insignificant (r = 0.287, p = 0.058) [ Table 3 ].
The correlation of age with cardiac T2*mrI values in patients with BTm indicated a significant and moderate inverse correlation (r = -0.519, p = 0.017). However, the correlation of age with hepatic T2*mrI values (r = -0.167, p = 0.312) and lIC (r = 201, p = 0.075) was poor and statistically insignificant [ Table 4 ].
We investigated the genotype distribution of HFe C282y and H63d mutations in our cohort. The HFe C282y mutation was not detected in any patients in our study. However, the HFe H63d mutation was detected in 12 (20.0%) patients. The genotype distribution of HFe H63d mutation (HH = 48, Hd = 10, dd = 2) was in accordance with the Hardy-Weinberg equilibrium (p = 0.138), indicating the absence of selection bias in our study. as shown in Table 5 , the carrier frequency of HFe H63d mutation did not differ significantly between patients with and without hepatic hemosiderosis [odd ratio (Or) = 2.33; 95% confidence interval (CI): 0.64-8.45; p = 0.190] as well as between patients with and without cardiac hemosiderosis [Or = 1.82; 95% CI: 0.50-6.52; p = 0.350] [ Table 5 ]. However, comparing patients with and without HFe H63d mutation indicated significantly higher plasma ferritin levels (1 903±993 vs. 992±683, p < 0.001) and iron levels (214.56±39.46 vs. 167.83±58.61, 
D I S C U S S I O N
Cardiac and hepatic hemosiderosis are the main causes of morbidity and mortality in patients with BTm. The results of our study indicated cardiac and hepatic hemosiderosis in 38.3% and 41.6% of the patients, respectively. different rates of cardiac and hepatic hemosiderosis were reported in previous studies. 20,22,24 mean age differences of the studied populations, variations in sample size, and of chelation regimes may considerably affect the incidence of cardiac and hepatic hemosiderosis in different studies. 19, 24 Interestingly, it is known that deferiprone results in preferential cardiac chelation whereas deferoxamine may be more effective for hepatic chelation. 19 also, our results are in accordance with some previously published studies that demonstrated a statistically significant inverse correlation between plasma ferritin levels and hepatic T2*mrI values (p = 0.001, r = -0.631) and indicated that plasma ferritin levels could accurately and thoroughly estimate hepatic iron load. [20] [21] [22] This result may be of great importance in unequipped centers where T2*mrI is unavailable. However, other studies have reported different correlation strengths ranging from no correlation to moderate correlation. 18, 25, 26 Our study indicated a weak correlation between plasma ferritin levels and cardiac T2*mrI values that was in accordance with previous studies. 21, 26, 27 However, in contrast to our result, yang et al, 19 in a recently published study reported a statistically significant strong correlation between serum ferritin levels and cardiac T2*mrI values. This may be explained by the fact that the vast majority of patients (97.5%) included in their study received poor chelation therapy. Similar to previous studies, 18, 26, 28 our study indicated a poor and statistically insignificant correlation between cardiac and hepatic T2*mrI values (p = 0.058, r = 0.287). The poor correlation of cardiac T2*mrI values with plasma ferritin levels as well as with hepatic T2*mrI values strongly suggest that plasma ferritin levels and hepatic T2*mrI values cannot thoroughly predict cardiac iron content. This finding emphasizes the importance of using cardiac T2*mrI as a noninvasive and precise procedure for estimating of cardiac iron overload instead of relying solely on ferritin levels or hepatic T2*mrI values. The possible mechanisms for poor or insignificant correlation between hepatic and cardiac T2*mrI values may be related to the organ-specific mechanisms of iron uptake and release. 29 also chelation therapy is usually more effective in eliminating iron from the liver than heart. 19 another important aspect of our study was that a statistically significant moderate correlation was seen between age and cardiac T2*mrI values while the correlation of age with hepatic T2*mrI values was weak and insignificant. Similar results have been reported previously. 18, 19, 28 Since the liver is the first organ to store iron in the body, most patients develop hepatic iron overload earlier in life. However, cardiac iron overload develops slowly in a time-dependent manner so that it progresses as the patient ages. Therefore, the age of patients has a more pronounced impact on the development of cardiac hemosiderosis relative to the development of hepatic hemosiderosis. The study by yang et al, 19 proposed that cardiac hemosiderosis should be assessed using T2*mrI in patients with BTm at six years of age. Iron overload cardiomyopathy (IOC) is the serious manifestation of iron deposition in the heart. The spectrum of symptoms of IOC ranges from asymptomatic in the early stage of disease to terminal heart failure in severely overloaded patients. early diagnosis and adequate medical therapy can reverse IOC and has a crucial role in the prevention and treatment of this disorder. 30 Our results showed that mrI is more sensitive and more precise than analysis of routine biochemical markers and we would like to reemphasize the advantage of using this technique for the early detection of cardiac iron overload in patients with BTm.
HFe H63d and C282y gene mutations are the common causes of genetic hemosiderosis. Interestingly, some previous studies have reported an increased frequency of HFe gene mutations in BTm patients. 8, 31 Our study investigated for the first time the role of HFe H63d and C282y mutations in the development of cardiac and hepatic hemosiderosis in Iranian patients with BTm. according to our results, the difference in genotype and allele distribution of HFe H63d mutation in patients with and without cardiac or hepatic hemosiderosis did not reach a significant level, indicating the futility of these mutations in conferring increased risk of cardiac and hepatic hemosiderosis. Similar results were reported by Turedi et al, 13 in a recently published study of 33 Turkish patients with BTm. However, in our study, an elevated plasma ferritin level was found in the carriers of HFe H63d mutation, which indicated the modulating effects of the HFe H63d mutation on biochemical iron markers. Coinheritance of HFe H63d mutation may enhance the iron overload in patients with BTm, which may necessitate a more intensive iron chelation therapy in these patients to prevent hemosiderosis development. Our recent results were in accordance with the results of some previously published studies that indicated a positive association between HFe H63d mutation and serum ferritin levels. 4, 6, 11 However, some other studies have not reported such an association. 32, 33 The possible reasons for these contradictory results may be related to variation in the study design (i.e., sample size, sample selection criteria) and the presence of genegene and gene-environment interactions in various studied populations. 34 The present study has some limitations: (i) the cross-sectional design of the study limited the inclusion of control group, (ii) the other polymorphisms of HFe gene were not investigated, and (iii) the study population was relatively small.
C O N C LU S I O N S
Cardiac T2*mrI should be done for all patients with BTm regardless of their serum ferritin levels or hepatic T2*mrI values. HFe H63d and C282y mutations are not major causes for development of cardiac and hepatic hemosiderosis in patients with BTm from the Zanjan province of Iran. However, a large-scale multi-center study in Iran is required to confirm these preliminary results.
